Drugs
RALEIGH, N.C., December 21, 2020 – Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Xeomin (incobotulinumtoxinA) for the treatment of patients aged 2 years and older with chronic sialorrhea, or drooling. Xeomin is the first and only FDA-approved neuromodulator with this indication and
0 Comments
Treatment for Chronic Kidney Disease-Associated Pruritus Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Korsuva Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus STAMFORD, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus
0 Comments
爱情是从告白开始的 电视剧最新章节免费阅读_爱情是从告白 ,任你躁二区在线播放最新章节列表_任你躁二区在线播放最新 WALTHAM, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) — Sobi™, an international biopharmaceutical company dedicated to rare diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Kineret (anakinra) for the treatment of deficiency of IL-1 receptor antagonist (DIRA). DIRA is an ultra-rare, autoinflammatory disease caused by
0 Comments
A study reveals the airflow patterns inside a passenger car and how open windows can increase or decrease COVID-19 transmission risk. Researchers studied how airflow changes inside a car may worsen or reduce COVID-19 transmission risk in a first-of-its-kind study. They observed that opening windows – the more windows, the better – created airflow patterns
0 Comments
Treatment for Pharmacologic Mydriasis Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi NEW YORK–(BUSINESS WIRE)–Dec. 29, 2020– Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted a New Drug Application (NDA) to the U. S. Food and Drug
0 Comments
December 18, 2020 — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Iclusig (ponatinib) for adult patients with chronic-phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors. The updated label includes
0 Comments
Understanding the correlation between metabolic syndrome and COVID-19 may be crucial to improved treatment and outcomes. The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become a global crisis affecting millions of people with more than 40 million confirmed cases worldwide and over a million COVID-19 related deaths. Particularly, the elderly
0 Comments
December 28, 2020 Audience: Consumer, Patient, Health Professional, Pharmacy Schaumburg, Illinois, Sunstar Americas, Inc. (SAI) is voluntarily recalling Paroex® Chlorhexidine Gluconate Oral Rinse USP, 0.12% products bearing an expiration date from 12/31/2020 – 9/30/2022 to the consumer level. This product may be contaminated with the bacteria Burkholderia lata. This is an expansion of the recall
Treatment for Schizophrenia, Bipolar Disorder FDA Accepts Alkermes’ Resubmission of New Drug Application for ALKS 3831 DUBLIN, Dec. 29, 2020 /PRNewswire/ – Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company’s New Drug Application (NDA) resubmission for ALKS 3831 (olanzapine/samidorphan) for the treatment of adults with schizophrenia and adults with
0 Comments
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA)
0 Comments
December 23, 2020 Audience: Consumers December 23, 2020 — Shane Erickson, Inc. is voluntarily recalling lot 2020/05/11 and MFG: 2020/05/10 L/N: 20200510-3 of imc Wash-Free Hand Sanitizer 50 ml, 100 ml, 300 ml and Wash Free Hand Sanitizer 300 ml lot 2020/05/11 and Thrifty White Pharmacy Wash-Free Hand Sanitizer 300 ml lot 2020/05/11 listed in
0 Comments
FDA Approves Gemtesa (vibegron) Tablets for the Treatment of Patients with Overactive Bladder (OAB) IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Dec. 23, 2020– Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for once-daily 75 mg Gemtesa (vibegron), a beta-3 adrenergic receptor (β3) agonist,
0 Comments
NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved Xpovio (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment
0 Comments
Healthy fats are an important part of a healthy, balanced diet. Fats are often considered to be dangerous due to its association with obesity, heart disease, high cholesterol, and diabetes. However, healthy fats are an essential part of the diet and play a crucial role in maintaining a healthy life. All fats are high in
0 Comments
FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug Administration (FDA) has approved Orgovyx (relugolix)
0 Comments
New research investigates a new way to reduce postoperative pain and minimize opioid use in people undergoing surgery. Opioids are a class of medications that interact with the opioid receptors in the body.  They can have many therapeutic purposes, including pain relief, controlling coughs, treating diarrhea, and help people get over certain addictions when prescribed
0 Comments
infigratinib Treatment for Cholangiocarcinoma of biliary tract BridgeBio Pharma And Affiliate QED Therapeutics Announce FDA Acceptance Of New Drug Application For Infigratinib For The Treatment Of Cholangiocarcinoma PALO ALTO, CA – December 1, 2020 – BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with
0 Comments
Bacterial infections are experienced by individuals globally. In developing countries, infections are considered one of the largest contributors of death. Antibiotics have been around for over a century, aimed at treating bacterial infections. Due to the prevalence of bacterial infections worldwide, antibiotics are commonly used in healthcare settings for therapeutic treatment. Antibiotics can be used
0 Comments
FDA Approves Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection December 21, 2020 — The U.S. Food and Drug Administration approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the treatment for Zaire ebolavirus (Ebolavirus) infection in adults and children. Ebanga blocks binding of the virus to the cell receptor, preventing its entry into the
0 Comments
Researchers studied the differences in blood pressure measurements taken from both arms. High blood pressure is one of the leading indicators of cardiovascular disease, which is the number one cause of death in the world. About 1.13 billion people suffer from high blood pressure, although risk factors such as unhealthy diet, sedentary lifestyle, smoking, and
0 Comments
ublituximab Treatment for Chronic Lymphocytic Leukemia TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) – TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the Company has initiated a rolling submission
0 Comments
21 December 2020 — AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent. Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 L858R mutations as detected by an
0 Comments
Sharing a simple meal each day might boost children’s self-esteem according to a new study. Children’s mental health is an important aspect of overall health, and increasing research in this field has shone a light on significant factors that can impact on children’s mental health and self-esteem. However, something as seemingly small as family mealtime
0 Comments
amivantamab Treatment for Non-Small Cell Lung Cancer Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License
0 Comments
South San Francisco, CA — December 1, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic rearranged during
0 Comments
brincidofovir Treatment for Smallpox Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox DURHAM, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the
0 Comments
FDA Approves Margenza (margetuximab-cmkb) for Patients with Pretreated Metastatic HER2-Positive Breast Cancer ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) —  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved Margenza, in
0 Comments